JP2003514910A - Ｈｉｖプロテアーゼ阻害剤としてのガンマ−ヒドロキシ−２−（フルオロアルキルアミノカルボニル）−１−ピペラジンペンタンアミド類 - Google Patents

Ｈｉｖプロテアーゼ阻害剤としてのガンマ−ヒドロキシ−２−（フルオロアルキルアミノカルボニル）−１−ピペラジンペンタンアミド類

Info

Publication number
JP2003514910A
JP2003514910A JP2001540095A JP2001540095A JP2003514910A JP 2003514910 A JP2003514910 A JP 2003514910A JP 2001540095 A JP2001540095 A JP 2001540095A JP 2001540095 A JP2001540095 A JP 2001540095A JP 2003514910 A JP2003514910 A JP 2003514910A
Authority
JP
Japan
Prior art keywords
hydroxy
dihydro
amino
alkyl
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001540095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003514910A5 (cg-RX-API-DMAC7.html
Inventor
タタ，ジエイムズ・アール
チヤツプマン，ケビン・テイー
ダフイー，ジヨウジフ・レスリー
ケビン，ナンシー・ジエイ
チエン，ユワン
ラノ，トーマス・エイ
チヤン，フエンチ
フユーニング，トレイシー
カーク，ブライアン・アンソニー
ルー，チジヤン
ラガバン，スバレカ
フライツ，フレツド・ジエイ
ペトリロ，ダニエル・イー
アームストロング，ジヨウジフ・デイー，ザ・サード
バルソローナ，リチヤード・ジエイ
アスキン，デイビツド
ホールナー，アール・スコツト
ピユリツク，ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2003514910A publication Critical patent/JP2003514910A/ja
Publication of JP2003514910A5 publication Critical patent/JP2003514910A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2001540095A 1999-11-24 2000-11-21 Ｈｉｖプロテアーゼ阻害剤としてのガンマ−ヒドロキシ−２−（フルオロアルキルアミノカルボニル）−１−ピペラジンペンタンアミド類 Withdrawn JP2003514910A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16747899P 1999-11-24 1999-11-24
US60/167,478 1999-11-24
US17705300P 2000-01-20 2000-01-20
US60/177,053 2000-01-20
PCT/US2000/032089 WO2001038332A1 (en) 1999-11-24 2000-11-21 Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors

Publications (2)

Publication Number Publication Date
JP2003514910A true JP2003514910A (ja) 2003-04-22
JP2003514910A5 JP2003514910A5 (cg-RX-API-DMAC7.html) 2008-01-17

Family

ID=26863215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001540095A Withdrawn JP2003514910A (ja) 1999-11-24 2000-11-21 Ｈｉｖプロテアーゼ阻害剤としてのガンマ−ヒドロキシ−２−（フルオロアルキルアミノカルボニル）−１−ピペラジンペンタンアミド類

Country Status (11)

Country Link
US (1) US6642237B1 (cg-RX-API-DMAC7.html)
EP (1) EP1242426B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003514910A (cg-RX-API-DMAC7.html)
AT (1) ATE377011T1 (cg-RX-API-DMAC7.html)
AU (1) AU777824B2 (cg-RX-API-DMAC7.html)
CA (1) CA2391643C (cg-RX-API-DMAC7.html)
CO (1) CO5261497A1 (cg-RX-API-DMAC7.html)
DE (1) DE60036961T2 (cg-RX-API-DMAC7.html)
ES (1) ES2295068T3 (cg-RX-API-DMAC7.html)
PE (1) PE20011025A1 (cg-RX-API-DMAC7.html)
WO (1) WO2001038332A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117009A1 (ja) * 2006-04-11 2007-10-18 Mitsubishi Tanabe Pharma Corporation ２，２－ジアルコキシエチルアミン化合物およびその製造方法
JP2017521416A (ja) * 2014-07-08 2017-08-03 ダウ アグロサイエンシィズ エルエルシー ３−ヒドロキシピコリン酸の製造方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
WO2001055326A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US7122376B2 (en) * 2001-11-01 2006-10-17 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
US7049146B2 (en) 2000-11-14 2006-05-23 Facet Analytical Services And Technology, Llc Calibration standards, methods, and kits for water determination
AU2002305720A1 (en) * 2001-05-30 2002-12-09 Huening, Tracy, T. Piperazine pentanamide hiv protease inhibitors
US6649761B2 (en) 2001-05-30 2003-11-18 Merck & Co., Inc. Process for preparing piperazinepentaneamide HIV protease inhibitors
US6835860B2 (en) 2002-02-01 2004-12-28 Merck & Co., Inc. Iodohydroxylation of olefins
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
WO2004027361A1 (en) * 2002-09-17 2004-04-01 University Of Virginia Patent Foundation Remote temperature sensing of small volume and related apparatus thereof
US7199240B2 (en) 2002-12-11 2007-04-03 Merck & Co., Inc. Reductive alkylation of saturated cyclic amines
ES2571779T3 (es) * 2002-12-13 2016-05-26 Ym Biosciences Australia Pty Inhibidores de cinasa a base de nicotinamida
TW574132B (en) * 2003-04-14 2004-02-01 Univ Nat Cheng Kung Integrated microfluidic electro-spray chip system and the analysis method thereof
US7161015B1 (en) * 2005-09-08 2007-01-09 The United States Of America As Represented By The Secretary Of The Navy Method of making 2-furylalkylketones
CA2762582A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
JP6122639B2 (ja) 2009-10-26 2017-04-26 メルク・シャープ・エンド・ドーム・コーポレイション インテグラーゼ阻害剤を含有する固形医薬組成物
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9173396B2 (en) 2010-10-22 2015-11-03 Bayer Intellectual Property Gmbh Heterocyclic compounds as pesticides
EP2632895B1 (en) 2010-10-28 2018-10-03 Merck Canada Inc. Hiv protease inhibitors
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
CN103929964A (zh) 2011-09-23 2014-07-16 拜耳知识产权有限责任公司 4-取代的1-苯基吡唑-3-甲酸衍生物作为对抗非生物植物胁迫的活性物质的用途
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
RU2015113091A (ru) 2012-09-11 2016-11-10 Мерк Шарп И Доум Корп. Ингибиторы протеазы вич
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
US10376583B2 (en) 2013-09-30 2019-08-13 Beth Israel Deaconess Medical Center, Inc. Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
US9737545B2 (en) 2013-12-19 2017-08-22 Merck Sharp & Dohme Corp. HIV protease inhibitors
WO2015095276A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015134366A1 (en) 2014-03-06 2015-09-11 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP3116862B1 (en) 2014-03-10 2019-04-17 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
EP2944955A1 (en) * 2014-05-13 2015-11-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Benchmark for LC-MS systems
CN104311479B (zh) * 2014-09-15 2016-06-15 西华大学 3,5-二碘-4-羟基吡啶的合成
TW201730188A (zh) * 2015-11-30 2017-09-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
WO2019175464A1 (en) 2018-03-14 2019-09-19 Orion Corporation Compounds useful as inhibitors of sodium-calcium exchanger (ncx)
AR114422A1 (es) 2018-03-30 2020-09-02 Syngenta Participations Ag Compuestos herbicidas
BR112021009046A2 (pt) 2018-11-12 2021-08-10 Syngenta Crop Protection Ag compostos herbicidas
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
IL103613A (en) 1991-11-08 1999-05-09 Merck & Co Inc Hiv protease inhibitors process and intermediats for their preparation and pharmaceutical compositions containing them
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
IL110255A (en) 1993-07-16 1998-12-06 Merck & Co Inc Formation and resolution of 2-tert-butylcarboxamido-piperazine
US5455351A (en) * 1993-12-13 1995-10-03 Abbott Laboratories Retroviral protease inhibiting piperazine compounds
PL314984A1 (en) 1993-12-15 1996-09-30 Merck & Co Inc Hiv protease inhibitors
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
TW438799B (en) * 1997-05-29 2001-06-07 Merck & Co Inc HIV protease inhibitor
WO1999033795A1 (en) * 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117009A1 (ja) * 2006-04-11 2007-10-18 Mitsubishi Tanabe Pharma Corporation ２，２－ジアルコキシエチルアミン化合物およびその製造方法
JPWO2007117009A1 (ja) * 2006-04-11 2009-08-20 田辺三菱製薬株式会社 ２，２−ジアルコキシエチルアミン化合物およびその製造方法
JP2017521416A (ja) * 2014-07-08 2017-08-03 ダウ アグロサイエンシィズ エルエルシー ３−ヒドロキシピコリン酸の製造方法

Also Published As

Publication number Publication date
CA2391643A1 (en) 2001-05-31
ATE377011T1 (de) 2007-11-15
AU777824B2 (en) 2004-11-04
CA2391643C (en) 2010-01-12
US6642237B1 (en) 2003-11-04
EP1242426A1 (en) 2002-09-25
EP1242426B1 (en) 2007-10-31
WO2001038332A1 (en) 2001-05-31
PE20011025A1 (es) 2001-10-12
CO5261497A1 (es) 2003-03-31
DE60036961D1 (de) 2007-12-13
ES2295068T3 (es) 2008-04-16
AU1790901A (en) 2001-06-04
DE60036961T2 (de) 2008-08-28

Similar Documents

Publication Publication Date Title
JP2003514910A (ja) Ｈｉｖプロテアーゼ阻害剤としてのガンマ−ヒドロキシ−２−（フルオロアルキルアミノカルボニル）−１−ピペラジンペンタンアミド類
CN111094243B (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
JP6349360B2 (ja) Ｃｂ２アゴニストとして有用なピリジン−２−アミド
KR101877187B1 (ko) 치환된 다이하이드로이소퀴놀린온 화합물
US11098010B2 (en) Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
TWI622578B (zh) Ｂ型肝炎抗病毒劑
US8153658B2 (en) Piperidine derivative or salt thereof
JP2000128782A (ja) アニリド誘導体含有ｃｃｒ５拮抗剤
CN108137507A (zh) 基于mdm2的蛋白水解调节剂和相关的使用方法
KR20030026979A (ko) 디시아노피리딘 유도체를 포함하는 의약
TWI583687B (zh) ２－氧雜－５－氮雜雙環［２．２．１］庚－３－基衍生物
TW201427953A (zh) 可作爲激酶調節劑之經雜芳基取代的吡啶化合物
JP2013504604A (ja) ウイルスポリメラーゼ阻害剤としてのキナゾリノン誘導体
WO2008007780A1 (fr) Dérivé du pentadiènamide
TW201629048A (zh) 醛固酮合成酶抑制劑
AU2021410119A1 (en) Tetrahydroquinoline derivative and medicinal use thereof
JP2007530516A (ja) 抗ウイルス剤として有用な４−カルボキシピラゾール誘導体
US20240228504A1 (en) Substituted tricyclic amides, analogues thereof, and methods using same
WO2002067683A1 (en) Hiv protease inhibitors supported on cation exchange resins for oral administration
US20040067216A1 (en) Hiv protease inhibitors supported on cation exchange resins for oral administration
JP2005513083A (ja) プロテアーゼ阻害剤
TW202214585A (zh) 經取代之異喹啉基甲基醯胺類、其類似物及使用其之方法
HK1193594A (en) Pyridin- 2 -amides useful as cb2 agonists
HK1193594B (en) Pyridin- 2 -amides useful as cb2 agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071116

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20101206